High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: Results of a phase II study

British Journal of Cancer

Volumn 85, Issue 9, 2001, Pages 1240-1246

  Cottu, P H ^a   Extra, J M ^a   Espie, M ^a   Marolleau, J P ^a   De Roquancourt, A ^a   Makke, J ^a   Miclea, J M ^a   Laurence, V ^a   Mayeur, D ^b   Lerebours, F ^a   Cuvier, C ^a   Marty, M ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

Advanced; Breast cancer; Chemotherapy; High dose

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; EPIRUBICIN; HEMOPOIETIC GROWTH FACTOR; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; APHERESIS; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; DRUG INFUSION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN TISSUE; INFECTION; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THROMBOCYTE TRANSFUSION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME;

EID: 0035798430     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2069     Document Type: Article

References (37)

1. Critique of the high dose chemotherapy studies in breast cancer: A positive look at the data
2. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America
3. Prognostic factors for prolonged progression free survival with high dose chemotherapy with autologous stem cell support for advanced breast cancer
4. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Cancer Cooperative Group
5. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer
6. High-dose epirubicin and cyclophosphamide every two weeks as first line chemotherapy for relapsing metastatic breast cancer patients
7. Epirubicin. An updated review of its pharmacodynamics and pharmacokinetics properties and therapeutic efficacy in the management of breast cancer
8. ESTIC position paper: High-dose chemotherapy for breast cancer, investigation should continue
9. Promising results of bimonthly chemotherapy with high dose cyclophosphamide and epirubicin in induction treatment of inflammatory cancer of the breast
10. Residual tumor cell in peripheral blood stem cells collections of 117 breast cancer patients evaluated by immunocytochemical technique
11. Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer
12. Efficacy and tolerance of vinorelbine and fluorouracile combination as first-line chemotherapy of advanced breast cancer: Results of a phase II study using a sequential group method
13. High-dose induction chemotherapy (HDIC) in breast cancer with metastases (MBC) at diagnosis
14. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22
15. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25
16. Hormonal therapy and chemotherapy
17. Cytokinetics and breast cancer chemotherapy
18. High dose chemotherapy and breast cancer
19. Evolving concepts in high-dose chemotherapy for breast cancer
20. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: Summation dose-intensity
21. Non parametric estimation from incomplete observations
22. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer
23. Commentary on PBT-1 study of high dose consolidation versus standard therapy in metastatic breast cancer
24. High-dose chemotherapy with hematopoietic stem cells transplantation for metastatic breast cancer: Results of the French Protocol PEGASE 04
25. High dose chemotherapy: Is it standard management for any common solid tumor?
26. A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autlogous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy
27. An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer
28. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer
29. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high dose chemotherapy with autologous stem cell support
30. Feasibility of multiple courses of high dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer
31. Factors correlated with progresion free survival after high dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer
32. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients
33. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with curability of leukemia
34. Conventional dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer
35. High-Dose chemotherapy with autologous stem cell support for breast cancer
36. An on-site audit of the south african trial of high-dose chemotherapy for metastatic breast cancer and associated publications